Nom anglais: Jumonji Domain-Containing Histone Demethylases
Descriptor UI:D056484
Tree Number:D08.811.682.690.416.388
Termes MeSH sélectionnés :
Predictive Value of Tests
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Jumonji Domain-Containing Histone Demethylases : Questions médicales les plus fréquentes",
"headline": "Jumonji Domain-Containing Histone Demethylases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Jumonji Domain-Containing Histone Demethylases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-10",
"dateModified": "2025-04-06",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Jumonji Domain-Containing Histone Demethylases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Dioxygenases",
"url": "https://questionsmedicales.fr/mesh/D049308",
"about": {
"@type": "MedicalCondition",
"name": "Dioxygenases",
"code": {
"@type": "MedicalCode",
"code": "D049308",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.690.416"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Jumonji Domain-Containing Histone Demethylases",
"alternateName": "Jumonji Domain-Containing Histone Demethylases",
"code": {
"@type": "MedicalCode",
"code": "D056484",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Danica Galonić Fujimori",
"url": "https://questionsmedicales.fr/author/Danica%20Galoni%C4%87%20Fujimori",
"affiliation": {
"@type": "Organization",
"name": "Department of Cellular and Molecular Pharmacology, University of California San Francisco; San Francisco, CA 94158, USA; Department of Pharmaceutical Chemistry, University of California San Francisco; San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), University of California San Francisco; San Francisco, CA 94158, USA. Electronic address: danica.fujimori@ucsf.edu."
}
},
{
"@type": "Person",
"name": "James E Longbotham",
"url": "https://questionsmedicales.fr/author/James%20E%20Longbotham",
"affiliation": {
"@type": "Organization",
"name": "Department of Cellular and Molecular Pharmacology, University of California San Francisco, 600 16th Street, Genentech Hall, San Francisco, California 94158, United States."
}
},
{
"@type": "Person",
"name": "Feng Li",
"url": "https://questionsmedicales.fr/author/Feng%20Li",
"affiliation": {
"@type": "Organization",
"name": "Department of Cell Biology, Key Laboratory of Cell Biology, National Health Commission of the PRC, Shenyang, China."
}
},
{
"@type": "Person",
"name": "Christopher J Schofield",
"url": "https://questionsmedicales.fr/author/Christopher%20J%20Schofield",
"affiliation": {
"@type": "Organization",
"name": "Chemistry Research Laboratory , University of Oxford , 12 Mansfield Road , Oxford OX1 3TA , United Kingdom."
}
},
{
"@type": "Person",
"name": "Anthony Tumber",
"url": "https://questionsmedicales.fr/author/Anthony%20Tumber",
"affiliation": {
"@type": "Organization",
"name": "Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford 12 Mansfield Road OX1 3TA Oxford UK christopher.schofield@chem.ox.ac.uk lennart.brewitz@chem.ox.ac.uk."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Evaluation of the focus reduction neutralization and ELISA tests compared to the plaque reduction neutralization test for the detection of antibodies against measles virus.",
"datePublished": "2024-10-05",
"url": "https://questionsmedicales.fr/article/39369472",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.biologicals.2024.101795"
}
},
{
"@type": "ScholarlyArticle",
"name": "Shifting Grounds-Facilitating Self-Care in Testing for Sexually Transmitted Infections Through the Use of Self-Test Technology: Qualitative Study.",
"datePublished": "2024-08-14",
"url": "https://questionsmedicales.fr/article/39141903",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2196/55705"
}
},
{
"@type": "ScholarlyArticle",
"name": "Towards improved point-of-care (POC) testing for patients with suspected sepsis: POC tests for host biomarkers and possible microbial pathogens.",
"datePublished": "2024-08-12",
"url": "https://questionsmedicales.fr/article/39135402",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/14737159.2024.2392283"
}
},
{
"@type": "ScholarlyArticle",
"name": "Current laboratory testing practices for mismatch repair deficiency and microsatellite instability testing: A survey-based review of current laboratory practices.",
"datePublished": "2024-07-30",
"url": "https://questionsmedicales.fr/article/39078096",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1093/ajcp/aqae094"
}
},
{
"@type": "ScholarlyArticle",
"name": "Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center.",
"datePublished": "2024-03-19",
"url": "https://questionsmedicales.fr/article/38520994",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.breast.2024.103715"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D010088"
},
{
"@type": "ListItem",
"position": 5,
"name": "Oxygénases",
"item": "https://questionsmedicales.fr/mesh/D010105"
},
{
"@type": "ListItem",
"position": 6,
"name": "Dioxygenases",
"item": "https://questionsmedicales.fr/mesh/D049308"
},
{
"@type": "ListItem",
"position": 7,
"name": "Jumonji Domain-Containing Histone Demethylases",
"item": "https://questionsmedicales.fr/mesh/D056484"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Jumonji Domain-Containing Histone Demethylases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Jumonji Domain-Containing Histone Demethylases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Jumonji Domain-Containing Histone Demethylases",
"description": "Comment diagnostiquer une dysfonction des Jumonji ?\nQuels marqueurs biologiques sont associés aux Jumonji ?\nLes biopsies sont-elles utiles pour le diagnostic ?\nQuels tests sanguins sont recommandés ?\nY a-t-il des tests d'imagerie pour ces enzymes ?",
"url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Predictive+Value+of+Tests&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Jumonji Domain-Containing Histone Demethylases",
"description": "Quels symptômes sont liés aux anomalies des Jumonji ?\nLes troubles neurologiques sont-ils associés ?\nY a-t-il des symptômes cutanés associés ?\nLes symptômes varient-ils selon le type de Jumonji ?\nLes symptômes sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Predictive+Value+of+Tests&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Jumonji Domain-Containing Histone Demethylases",
"description": "Peut-on prévenir les dysfonctionnements des Jumonji ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nY a-t-il des vaccins pour prévenir ces dysfonctionnements ?\nL'éducation génétique est-elle importante ?\nLes conseils diététiques peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Predictive+Value+of+Tests&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Jumonji Domain-Containing Histone Demethylases",
"description": "Quels traitements sont disponibles pour les dysfonctionnements des Jumonji ?\nLes médicaments peuvent-ils cibler les Jumonji ?\nY a-t-il des traitements naturels recommandés ?\nLes traitements sont-ils personnalisés ?\nLes thérapies combinées sont-elles efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Predictive+Value+of+Tests&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Jumonji Domain-Containing Histone Demethylases",
"description": "Quelles complications peuvent survenir avec les dysfonctionnements des Jumonji ?\nLes complications sont-elles graves ?\nY a-t-il des complications à long terme ?\nLes complications sont-elles réversibles ?\nLes complications varient-elles selon le type de Jumonji ?",
"url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Predictive+Value+of+Tests&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Jumonji Domain-Containing Histone Demethylases",
"description": "Quels sont les facteurs de risque pour les dysfonctionnements des Jumonji ?\nL'âge est-il un facteur de risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'exposition à des toxines est-elle un facteur ?\nLe mode de vie influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D056484?mesh_terms=Predictive+Value+of+Tests&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des Jumonji ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses d'expression génique peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés aux Jumonji ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux de méthylation des histones et l'expression des gènes sont des marqueurs clés."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles utiles pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les biopsies peuvent aider à évaluer l'expression des Jumonji dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont recommandés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests pour mesurer les niveaux de protéines associées aux Jumonji peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests d'imagerie pour ces enzymes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'imagerie ne permet pas de diagnostiquer directement les Jumonji."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux anomalies des Jumonji ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de croissance, des anomalies développementales et des cancers peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques sont-ils associés ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements neurologiques peuvent être liés à des mutations des Jumonji."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines anomalies cutanées peuvent être observées, notamment dans des syndromes spécifiques."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de Jumonji ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, différents types de Jumonji peuvent entraîner des symptômes variés selon leur fonction."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend de la gravité et de la nature de la dysfonction des Jumonji."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les dysfonctionnements des Jumonji ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider à la prévention ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les individus à risque de dysfonctionnements."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins pour prévenir ces dysfonctionnements ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il n'existe pas de vaccins spécifiques pour prévenir les dysfonctionnements des Jumonji."
}
},
{
"@type": "Question",
"name": "L'éducation génétique est-elle importante ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur les risques génétiques peut aider à la prévention et à la détection précoce."
}
},
{
"@type": "Question",
"name": "Les conseils diététiques peuvent-ils aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir la santé cellulaire, mais ne prévient pas directement."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les dysfonctionnements des Jumonji ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies géniques et des inhibiteurs spécifiques sont en cours d'étude."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils cibler les Jumonji ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments expérimentaux ciblent les Jumonji pour traiter des cancers."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels recommandés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches nutritionnelles et phytothérapeutiques sont explorées, mais peu prouvées."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques des Jumonji."
}
},
{
"@type": "Question",
"name": "Les thérapies combinées sont-elles efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent que les thérapies combinées peuvent améliorer les résultats cliniques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les dysfonctionnements des Jumonji ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des cancers, des troubles métaboliques et des anomalies développementales peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles graves ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines complications peuvent être potentiellement mortelles si non traitées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications chroniques peuvent se développer, affectant la qualité de vie."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le type de Jumonji ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent varier en fonction du type de Jumonji impliqué."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les dysfonctionnements des Jumonji ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs génétiques, environnementaux et liés au mode de vie peuvent influencer le risque."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains dysfonctionnements des Jumonji sont plus fréquents avec l'âge."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies génétiques augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines est-elle un facteur ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certaines toxines peut augmenter le risque de dysfonctionnements."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie malsain peut accroître le risque de dysfonctionnements des Jumonji."
}
}
]
}
]
}
Measles is an infectious febrile sickness caused by the measles virus (MeV). Despite an effective vaccine, regional elimination of measles remains a global priority and still faces challenges. To esti...
Chlamydia remains prevalent worldwide and is considered a global public health problem. However, testing rates among young sexually active people remain low. Effective clinical management relies on sc...
This study aimed to (1) pilot-test STT used in clinical practice and (2) investigate the experiences of patients who have completed a self-test for chlamydia and gonorrhea....
The study was conducted as a qualitative study inspired by the methodology of participatory design. Ethnographic methods were applied in the feasibility study and the data analyzed were inspired by th...
The findings from the feasibility study, such as lack of signposting and adequate information, led to the final modifications of the self-test technology and made it possible to implement it in clinic...
Accessible health care services are crucial in preventing and reducing the impact of sexually transmitted infections and STT may have the potential to increase testing uptake as it takes into account ...
Sepsis is a heterogeneous syndrome often misdiagnosed. Point-of-care (POC) diagnostic tests are commonly used to guide decision and include host biomarkers and molecular diagnostics....
The diagnostic and prognostic accuracy of established and emerging biomarkers for sepsis, including procalcitonin (PCT) soluble urokinase plasminogen activator receptor (suPAR), presepsin, TRAIL/IP-10...
The rising benefits of the combined use of POC biomarkers with molecular diagnostics in daily clinical routine appear to outperform conventional practices in terms of reduced turnaround time, timely d...
To describe mismatch repair (MMR) and microsatellite instability (MSI) testing practices in laboratories using the College of American Pathologists (CAP) MSI/MMR proficiency testing programs prior to ...
Data from supplemental questionnaires provided with the 2020-B MSI/MMR programs to 542 laboratories across different practice settings were reviewed. Questionnaires contained 21 questions regarding th...
Domestic laboratories test for MSI/MMR more often than international laboratories (P = .04) and academic hospitals/medical centers test more frequently than nonhospital sites/clinics (P = .03). The mo...
The results demonstrate the state of MMR and MSI testing in laboratories prior to the publication of the CAP/AMP best practice guidelines, highlighting differences between various laboratory types. Th...
It remains unclear whether patients with HER2-negative, low-estrogen receptor (ER-low)-positive early breast cancer (BC) benefit from Oncotype DX® (ODX) testing....
We conducted a retrospective review of cases referred for ODX testing over a seven-year period from a breast biomarker testing referral center (n = 854). For each case, we recorded the ODX Recurrence ...
We identified 27 cases (3.2%) that met our criteria for ER-low. Of these, 92.6% had a high RS (>25), and 7.4% had a RS of 25. All cases with ≤10% ER nuclear positivity had a high RS. Most ER-low cases...
ODX does not appear to add significant additional information to inform treatment decisions for most patients with ER-low BC. Incorporating weak ER staining intensity in addition to low percentage of ...
This study aimed to quantify test-retest reliability and minimal detectable change (MDC) of the four commonly used functional tests in older adults with a high risk of falling....
The cross-sectional study was conducted with 30 community-dwelling older adults (26 females, 4 males; mean age: 73.7±6.0 years; range, 65 to 88 years) with a high fall risk identified by the Thai fall...
The four functional tests had ICC in the range of 0.92 to 0.97. The SEM values of the CGS, FGS, TUG, FTSST, and 6MWT were 0.06 m/sec, 0.04 m/sec, 1.10 sec, 1.30 sec, and 20.60 m, respectively. The MDC...
All functional tests demonstrated excellent test-retest reliability. The SEM and MDC...
Germline testing is important in prostate cancer and evaluation can be complex....
We instituted a monthly multi-disciplinary virtual genetics tumor board (7/2021-3/2022). Participants and panelists were surveyed on usefulness and acceptability....
101 participants attended a session, and 77 follow-up surveys were completed. Over 90% participants and 100% panelists endorsed usefulness of the case discussions and usability of the technology. The ...
A multidisciplinary genetics board was successfully developed to address complexity in prostate cancer genetics. The virtual platform may enhance dissemination of expertise where there are regional ga...
The American Academy of Sleep Medicine commissioned a task force of clinical experts in pediatric sleep medicine to review published literature on performing the Multiple Sleep Latency Test (MSLT) and...
The aim of this study was to investigate attitudes and routine procedures in point of care testing (POCT) among non-laboratory and laboratory healthcare professionals in Croatia....
The Working Group (WG) for POCT of the Croatian society of medical biochemistry and laboratory medicine has designed two anonymous surveys for laboratory staff and non-laboratory staff with a total of...
A total of 112 non-laboratory healthcare professionals and 50 laboratories participated in the survey, which represents a response rate of 0.25% for non-laboratory professionals and 27% for MBLs. The ...
The majority of participants consider POCT as a medical tool that enables better patient care but there is still a lack of communication between laboratory and clinical staff. The study identified som...
Background The optimal dose of tenecteplase in acute ischemic stroke remains to be defined. We present a pooled analysis of the 2 NOR-TESTs (Norwegian Tenecteplase Stroke Trials) exploring the efficac...